stoxline Quote Chart Rank Option Currency Glossary
  
Moleculin Biotech, Inc. (MBRX)
5.54  0.86 (18.38%)    03-27 16:00
Open: 4.8
High: 5.688
Volume: 88,464
  
Pre. Close: 4.68
Low: 4.75
Market Cap: 12(M)
Technical analysis
2024-03-28 8:16:09 AM
Short term     
Mid term     
Targets 6-month :  7.26 1-year :  8.48
Resists First :  6.21 Second :  7.26
Pivot price 1.81
Supports First :  2.62 Second :  0.4
MAs MA(5) :  4.32 MA(20) :  1.52
MA(100) :  0.77 MA(250) :  0.67
MACD MACD :  1 Signal :  0.4
%K %D K(14,3) :  81.7 D(3) :  75.7
RSI RSI(14): 82.1
52-week High :  6.21 Low :  0.33
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MBRX ] has closed below upper band by 5.8%. Bollinger Bands are 1591.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.69 - 5.72 5.72 - 5.75
Low: 4.69 - 4.72 4.72 - 4.74
Close: 5.49 - 5.54 5.54 - 5.59
Company Description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Headline News

Thu, 28 Mar 2024
Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World

Thu, 28 Mar 2024
Research Analysts Offer Predictions for Moleculin Biotech, Inc.'s FY2028 Earnings (NASDAQ:MBRX) - Defense World

Wed, 27 Mar 2024
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity – Company Announcement - FT ... - Financial Times

Wed, 27 Mar 2024
Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML - Seeking Alpha

Wed, 27 Mar 2024
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - PR Newswire

Tue, 26 Mar 2024
Where Will Moleculin Biotech Inc (MBRX) Stock Go Next After It Is Down 40.59% in a Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 4.6 (%)
Held by Institutions 15.5 (%)
Shares Short 9 (K)
Shares Short P.Month 15 (K)
Stock Financials
EPS -13.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.69
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.8 %
Return on Equity (ttm) -76.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -13.23
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio -0.42
PEG Ratio 0
Price to Book value 0.47
Price to Sales 0
Price to Cash Flow -0.52
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android